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The objective of this study was to test whether macromolecule oxidative damage and altered enzy-
matic antioxidative defenses occur in patients with medium-chain acyl coenzyme A dehydrogenase 
(MCAD) deficiency. We performed a cross-sectional observational study of in vivo parameters of lipid 
and protein oxidative damage and antioxidant defenses in asymptomatic, non-stressed MCAD-defi-
cient patients and controls. Patients were subdivided into three groups, based on therapy: patients 
without prescribed supplementation, patients with L-carnitine supplementation, and patients with 
L-carnitine plus riboflavin supplementation.
Compared to healthy controls, non-supplemented MCAD-deficient patients and patients receiving 
L-carnitine supplementation displayed decreased plasma sulfhydryl content (indicating protein oxi-
dative damage). Increased erythrocyte superoxide dismutase activity in patients receiving L-carnitine 
supplementation probably reflects a compensatory mechanism to scavenge reactive species forma-
tion. The combination of L-carnitine plus riboflavin was not associated with oxidative damage.
These are the first indications that MCAD-deficient patients are subjected to protein oxidative dam-
age and that combined supplementation of L-carnitine and riboflavin may prevent these biochemical 
alterations. The results suggest involvement of free radicals in the pathophysiology of MCAD deficien-
cy. The underlying mechanisms behind the increased SOD activity upon L-carnitine supplementation 
need to be determined. Further studies are necessary to determine the clinical relevance of oxidative 
stress, including the possibility of antioxidant therapy.
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INTRODuCTION
Medium-chain acyl coenzyme A dehydrogenase (MCAD) deficiency [OMIM 201450] is the most com-
mon inherited disorder of mitochondrial fatty acid oxidation (mFAO) 1. Acute clinical presentation 
classically involves infants in the first five years of life 2. During periods with increased metabolic stress, 
fasting can precipitate acute symptoms, such as drowsiness or lethargy, sometimes progressing into 
coma or sudden death. Pathognomonic metabolite profiles in plasma or whole blood consist of 
increased concentrations of medium-chain fatty acids and their carnitine derivatives 3. Treatment con-
sists of prevention of prolonged fasting, an emergency regimen and may include supplementation 
of vitamins (L-carnitine and/or riboflavin), but evidence for any treatment is limited 1. The prognosis 
is very good after diagnosis, to which neonatal bloodspot screening (NBS) programs have made 
important contributions 4,5.
Oxidative stress can be defined as a state where the production of reactive species (RS) cannot 
be compensated for by the antioxidant defense, i.e. RS removal capacity, leading to macromolecule 
damage 6. The intimate relationship between mFAO, electron transport and oxidative phosphoryla-
tion justifies the study of oxidative stress in human disorders of mFAO 1. Macromolecule oxidative 
damage, impaired antioxidant defense and defect mitochondrial energy homeostasis have been 
demonstrated after incubation of rat brain, liver and skeletal muscle preparations with medium-chain 
fatty acid metabolites 7–10. Additionally, evidence for oxidative stress in mFAO defects was reported in 
various genetic mouse models 11,12.
The objective of this study was to substantiate whether macromolecule oxidative damage and 
altered antioxidative defense occur in patients with MCAD deficiency. We determined parameters 
of lipid and protein oxidative damage and enzymatic antioxidant defenses in blood samples that 




The study was approved by the Ethics Committee of the University Medical Center Groningen. Written 
informed consent was obtained from all patients and/or their parents.
MCAD-deficient patients were recruited from the Section of Metabolic Diseases, Beatrix Children’s 
Hospital, University Medical Center Groningen, Groningen, The Netherlands. Blood samples from 
27 MCAD-deficient patients (9 males, 18 females; median age 5.3 years, age range 0-27 years) were 
obtained during normal hospital visits. The complete group of patients was subdivided into three 
groups, based on the treatment provided. In our practice, we aim to normalize of plasma free car-
nitine concentrations (i.e. >16 μmol/l) in case we prescribe L-carnitine (30-50 mg/kg/d). Although 
riboflavin supplementation is not routinely prescribed, some older patients in our cohort still use this 
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supplementation, which they are familiar with. In those patients, riboflavin was dosed 50-150 mg/d, 
according to Duran et al. 13.
Biological sample collection and preparation
Blood samples from patients and controls were processed and stored by the same procedure. Blood 
samples from 12 age- and gender-matched control subjects (6 males and 6 females; median age 
10.0 years, age range 3-27 years) were recruited anonymously from the laboratory of the general 
practitioners’ service in Groningen, The Netherlands. At the time of sampling, no blood samples from 
younger children were available.
After venous puncture and collection in heparinized vials, plasma and cells were separated by 
centrifugation at 3000 x g for 10 minutes at 4°C. Plasma was removed by aspiration and stored at -80°C 
until further analysis. After plasma separation, erythrocytes samples were washed 3 times with cold 
NaCl 0.9% in equal volumes of erythrocytes and NaCl, and centrifuged for 10 minutes at 800 x g, after 
each washing. Lysates were prepared by addition of 1 ml of distilled water to 100 μL of washed eryth-
rocytes and subsequent storage at −80 °C until determination of the antioxidant enzyme activities.
Plasma analysis
Thiobarbituric acid reactive species (TBA-RS), a measure for malondialdehyde which is a parameter of 
lipid oxidative damage, were determined spectrophotometrically in plasma according to the method 
described by Esterbauer and Cheeseman 14. TBA-RS were expressed in nmol/mg protein.
Sulfhydryl content, a parameter of protein oxidative damage, was determined in plasma spectro-
photometrically based on the reduction of 5.5’dithio-bis (2-nitrobenzoic acid) by thiols, yielding a 
yellow derivative 15. The sulfhydryl content is inversely correlated to oxidative damage to proteins 
and results were reported as μmol/L. Carbonyl content, a parameter of protein oxidative damage, 
was determined in plasma spectrophotometrically as previously described by Levine et al.16. Plasma 
carbonyl content is expressed as nmol/mg protein.
Plasma protein concentration was determined according to the Biuret method using a commercial 
kit (Labtest Kit®, Lagoa Santa, Minas Gerais, Brazil).
Erythrocyte antioxidant analysis
Antioxidant enzyme activities were determined spectrophotometrically in erythrocyte lysates. 
Superoxide dismutase (SOD) converts superoxide radicals into hydrogen peroxide. Cytosolic SOD 
activity was determined using a kit (RANSOD®, Randox Laboratories, Antrim, United Kingdom), and 
isrepresented as units/mg protein. Catalase (CAT) catalyzes the degradation of hydrogen peroxide 
into molecular oxygen and water. CAT activity was determined according to the method described 
by Aebi 17. Glutathione peroxidase (GPx) catalyzes the conversion of glutathione (GSH) and hydrogen 
peroxide into glutathione disulfide and water. GPx activity was measured using a kit (RANSEL®, Ran-
dox Laboratories, Antrim, United Kingdom). Erythrocyte GSH is a parameter of the non-enzymatic 
antioxidant defense. GSH concentrations were measured according to Browne and Armstrong 18 and 
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expressed as nmol/mg protein. Total antioxidant status (TAS) represents the quantity of tissue anti-
oxidants and was measured using a kit (Randox, Antrim, United Kingdom). The results are expressed 
in mmol/l. Protein content of erythrocyte lysates was determined by the method of Lowry. The final 
enzymatic activities are presented as percentage of control values.
Statistical analysis
Statistical analysis was performed using GraphPad Prism version 5.00 for Windows (GraphPad Soft-
ware, San Diego California USA, www.graphpad.com) and SPSS version 20 (International Business 
Machines Corp., Armonk New York, USA). Data were tested for statistically significant outliers using the 
Grubbs’ test with a conservative approach (alpha = 0.01) (http://graphpad.com/quickcalcs/Grubbs1.
cfm). Normality of the data was assessed using the Shapiro-Wilk normality test. Differences between 
the complete group of patients and controls were tested using either the two-tailed unpaired Stu-
dent’s t-test or Mann-Whitney test. Differences between patient subgroups and the control group 
were tested by the Kruskal-Wallis test and followed by the Dunn’s multiple comparison test when 
the p-value was significant. Correlations were analyzed with either Pearson’s analysis or Spearman’s 
analysis. In case of a correlation between outcome parameter and age, multiple linear regression 
was performed. Non-parametric data were log-transformed before linear regression. Differences were 
considered statistically significant at p<0.05.
RESuLTS
Table 1 summarizes the patient characteristics. All patients had an ACADM genotype that has been 
associated with clinical symptoms. In all patients, plasma acylcarnitine profiles and urinary organic 
acid analysis were severely abnormal, demonstrating the classical biomarkers of the disease at the 
time of the study (data not shown).
Parameters of macromolecule oxidative damage and antioxidant defense in controls and MCAD-
deficient patients were not influenced by the ACADM genotype (Table 2). Plasma TBA-RS values 
appeared significantly increased in MCAD-deficient patients, and correlated negatively to age in the 
patient group only (r2 0.25, p<0.05). Subdivision of the patient group according to treatment showed 
no significant differences in TBA-RS concentrations between the different groups.
We observed that plasma sulfhydryl content, which is inversely related to protein oxidative damage, 
was significantly decreased in MCAD-deficient patients when compared to controls (p < 0.05, Table 
2). After correction for age, data in both the patient group without supplementation (median 541.4 
μmol/L, range 445.9-641.9 μmol/L, p<0.05), and the patient group with L-carnitine supplementation 
(median 536.5 μmol/L, range 531.6-565.9 μmol/L, p<0.05) indicated oxidation of sulfhydryl groups 
(Figure 1). Addition of riboflavin to L-carnitine supplementation appeared to be effective in prevent-
ing protein oxidative damage. In contrast, carbonyl levels, which are products of protein oxidation, 
were similar in MCAD-deficient patients and controls.
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Plasma TAS was significantly increased in MCAD-deficient patients when compared to controls 
(Table 2). Subdivision according to treatment showed that this effect was mostly attributable to the 
non-supplemented patient group (p=0.08) however, treatment groups did not differ significantly from 
the control group. Erythrocyte activities of SOD and CAT were significantly increased in the complete 
group of MCAD-deficient patients, compared to controls (Table 2). L-carnitine supplementation was 
associated with significantly higher SOD activities (median 325%, range 126-540%, p<0.05, Figure 2), 
and plasma free carnitine concentrations correlated with SOD activities in MCAD-deficient patients 
Table 1: Characteristics of the MCAD-deficient patients and control group
Patient Gender Age NBS Supplementation Allele 1 Allele 2
(no.) (m / f ) (years) (yes / no) (no / C / C+R)    
1 m 5.6 yes no c.985A>G c.985A>G
2 f 1.5 yes no c.985A>G c.985A>G
3 f 2.1 yes no c.233T>C c.233T>C
4 m 18.7 no no c.985A>G c.157C>T
5 f 5.7 yes no c.985A>G c.985A>G
6 f 3.6 yes no c.985A>G c.985A>G
7 f 1.5 yes no c.985A>G c.233T>G
8 f 0.0 yes no c.985A>G c.985A>G
9 f 4.3 yes no c.985A>G c.985A>G
10 f 1.7 yes no c.985A>G c.985A>G
11 m 3.1 yes no c.985A>G c.985A>G
12 m 2.9 yes no c.985A>G c.789A>C
13 m 0.8 yes no c.985A>G c.789A>C
14 m 5.5 yes no c.985A>G c.789A>C
15 f 2.9 yes C c.985A>G c.985A>G
16 f 3.4 yes C c.985A>G c.985A>G
17 f 26.0 no C c.985A>G c.985A>G
18 f 11.3 no C c.985A>G c.985A>G
19 f 4.9 yes C c.985A>G c.985A>G
20 m 5.9 yes C c.985A>G c.985A>G
21 m 5.3 yes C c.985A>G c.985A>G
22 m 8.4 no C + R c.985A>G c.985A>G
23 f 8.9 no C + R c.985A>G c.985A>G
24 f 12.7 no C + R c.985A>G c.985A>G
25 f 18.3 no C + R c.985A>G c.985A>G
26 f 21.4 no C + R c.985A>G c.985A>G
27 f 23.6 no C + R c.985A>G c.985A>G
Legend: No, no supplementation; C, carnitine supplementation; C+R, carnitine and riboflavin supplementation; NBS, 
identified by the Dutch population NBS program. Median age and range are depicted for the control group.
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(Pearson r 0.398; p<0.05). Riboflavin supplementation had no additive effect (Figure 2). Associations 
between supplementation and CAT activities were not found. The anti-oxidative parameters did not 
correlate with age.
Table 2. Parameters of oxidative damage and antioxidant defense in plasma and erythrocyte lysates from controls 
and MCAD-deficient patients. 
Parameter Controls Patients p value
median range n median range n
TBA-RS (nmol/mg protein) 0.018 0.007-0.071 12 0.037 0.010-0.092 26 0.040#
Sulfhydryl (μmol/L) 613.7 526.7-654.1 12 548.8 445.9-641.9 27 0.000*
Carbonyl (nmol/mg protein) 0.22 0.12-0.26 12 0.21 0.11-0.28 27 0.737
SOD (%) 91.7 9.3-194.7 11 194.2 22.7-540.0 26 0.015*
CAT (%) 94.5 79.7-136.6 12 129.8 68.6-353.6 25 0.014#
GPx (%) 98.0 64.5-164.9 12 107.5 20.0-200.0 26 0.376
GSh (nmol/mg protein) 3.46 2.05-6.56 12 3.30 0.23-6.20 25 0.224
TAS (mmol/l) 0.50 0.39-1.12 12 0.65 0.46-1.11 27 0.046#
Legend: No, no supplementation; C, carnitine supplementation; C+R, carnitine and riboflavin supplementation. TBA-
RS: Thiobarbituric acid reactive species; SOD: superoxide dismutase; CAT: catalase activity: GPx: glutathione peroxi-








































Figure 1. Plasma sulfhydryl content in controls and MCAD-deficient patients, according to their treatment. 
Legend: No, no supplementation; C, carnitine supplementation; C+R, carnitine and riboflavin supplementation. * p < 




Macromolecule oxidative damage and impaired antioxidant defenses have been reported to play a 
role in the pathophysiology of several inherited metabolic disorders and the parameters have been 
suggested as biomarkers for follow up 19,20. Previous experimental studies in rat tissue preparations 
incubated with medium-chain fatty acid metabolites 7–10 and genetic mouse models 11,12 demon-
strated a relationship between macromolecule oxidative damage, impaired antioxidant defense and 
defective mFAO. MCAD-deficient patients display abnormal medium-chain fatty acid metabolite 
profiles in plasma and urine under normal, unstressed circumstances, even though they are clinically 
asymptomatic. Therefore, this study evaluated lipid and protein oxidative damage and the antioxidant 
status in MCAD-deficient patients under these normal, unstressed circumstances.
This study demonstrates decreased sulfhydryl contents and altered antioxidant defense in MCAD-
deficient patients. Decreased sulfhydryl indicates protein oxidative damage. Two thirds of the sulfhy-
dryl groups are protein bound and the remaining is a component of small molecules, such as GSH, a 
well-known effective antioxidant 15. Sulfhydryl groups also act as free radical scavengers preventing 
lipid oxidative damage 15. Several in vitro studies reported mitochondrial dysfunction and oxidative 
damage after incubation with metabolites accumulating in MCAD deficiency 7–10. In rat brain, octanoic 
and decanoic acid caused uncoupling of mitochondrial oxidative phosphorylation, mitochondrial cy-
tochrome c release, increased lipid and protein oxidation damage, and decreased GSH levels 8. Scaini 
et al. recently demonstrated similar effects in preparations of rat liver and skeletal muscle cells, where 
TBA-RS (lipid peroxidation) and carbonyl content (protein oxidation) were increased, and muscle GSH 
was decreased 9.
The theoretical rationale in favor of L-carnitine supplementation in MCAD deficiency is to reduce 
the number and severity of metabolic decompensations by (a) correcting the secondary carnitine de-

























Figure 2. SOD activities in controls and MCAD-deficient patients, according to their treatment. 
Legend: No, no supplementation; C, carnitine supplementation; C+R, carnitine and riboflavin supplementation. * p < 
0.05. Boxes represent interquartile ranges with median, whiskers indicate ranges.
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intramitochondrial acyl-CoA/CoA ratios, and (d) the antioxidant effects of carnitine 21. Nevertheless, 
there is no systematic clinical study supporting routine L-carnitine supplementation in most inherited 
metabolic diseases, including MCAD deficiency 22. The role of L-carnitine supplementation in MCAD 
deficiency therefore remains a matter of debate.
Interestingly, our study may support the rationale against L-carnitine supplementation, as sulfhydryl 
content was decreased and SOD activity was increased in patients with MCAD deficiency receiving 
L-carnitine. L-carnitine supplementation increases (acyl)carnitine concentrations in blood and also 
stimulates the carnitine cycle, transporting acyl-CoA from the cytosol into the mitochondrial matrix, 
thereby increasing intramitochondrial acyl-CoA concentrations 1. Tonin et al. recently reported the 
effect of incubating cerebral cortical cells from developing rats with high concentrations of medium-
chain acylcarnitines (hexanoylcarnitine, octanoylcarnitine, decanoylcarnitine and cis-4-decenoylcar-
nitine, 0.01 - 1.0 mM) 10. In particular, decanoylcarnitine was responsible for lipid and protein oxidative 
damage. Sauer et al. found no negative effect of medium-chain acylcarnitines (with chain-lengths 
until octanoylcarnitine) on mitochondrial respiratory chain enzyme activities in bovine heart mito-
chondria 23. Nevertheless, octanoyl-CoA was found to inhibit complex III, unlike any other acyl-CoA 
ester. Octanoyl-CoA is the most important substrate of MCAD and hence, although speculative, may 
accumulate even more in case of L-carnitine supplementation in combination with MCAD deficiency. 
Koeth et al. recently demonstrated in studies in humans and mice that free carnitine concentrations 
can promote artherosclerosis, via the formation of trimethylamine-N-oxide from carnitine by intestinal 
microbiota 24.
Riboflavin is the precursor of flavin adenine dinucleotide (FAD), an essential cofactor of many intra-
mitochondrial enzymes, including MCAD. Duran et al. studied the in vitro MCAD enzyme activity in 
lymphocytes from five MCAD-deficient patients before and after three weeks of riboflavin supplemen-
tation at a dose of 50-150 mg/day 13. Octanoyl-CoA dehydrogenase activity at least doubled in these 
patients after supplementation. Although this study did not discriminate between a specific increase 
of residual MCAD enzyme activity, a general increase of octanoyl-CoA dehydrogenase activity, or a 
combination, this has been the theoretical basis behind riboflavin supplementation in a subset of our 
older MCAD-deficient patients. In our study, patients receiving L-carnitine and riboflavin displayed 
normal sulfhydryl concentrations and SOD activities in contrast to patients with only L-carnitine 
supplementation. Our observations suggest an antioxidant role of riboflavin as described by Depeint 
et al.25, which could be explained by the chaperone function enhancing folding efficiency of MCAD 
protein in patients carrying a missense mutation in the ACADM gene 26.
Several methodological aspects of this study need to be discussed. First, it was difficult to obtain 
age- and gender-matched control samples, especially for the younger group of patients. Second, this 
is an observational cross-sectional study in samples that were obtained during normal hospital visits, 
which only enables us to speculate about causal relations. Third, the studied parameters showed 
large ranges, which can be partially explained by the inter-assay variability. In addition, we studied 
parameters in biological samples (blood) from our patients. It is important to realize that blood 
carnitine concentrations do not necessarily reflect tissue homeostasis, and blood oxidative stress 
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parameters may thus be no reflection of oxidative stress in the liver 27. The MCAD-deficient mouse 
model is characterized incompletely 28,29 and would facilitate mechanistic studies under acute and 
chronic conditions, discriminating contributions of different oxygen-consuming organs such as the 
brain, liver, heart and muscle.
Summarizing, we demonstrate oxidative damage and altered antioxidant status in asymptomatic 
MCAD-deficient patients. Population NBS programs for the disorder identify increasing numbers of 
patients, whose metabolite profiles never normalize. Although in vitro studies suggest that these 
metabolites may contribute to oxidative damage, their increased concentrations have never been 
associated with any clinical phenotype. Interesting experimental data originate from animal stud-
ies. Ibdah et al. studied ageing heterozygotes of a knock-out mouse model of long-chain mFAO, in 
which hepatic steatosis and insulin resistance were associated with reduced liver GSH and increased 
antioxidant enzyme activities 11. These observations suggest that oxidative damage, hepatic steatosis 
and insulin resistance are intimately related under circumstances of perturbed mFAO. Data from large 
follow-up cohort studies of MCAD-deficient patients until adulthood are not yet available.
CONCLuSIONS
MCAD-deficient patients display oxidative damage and altered antioxidant defense. Due to the 
intimate relationships between mFAO, electron transport and oxidative phosphorylation, RS may be 
generated by different simultaneous actions. Patients receiving both L-carnitine and riboflavin did not 
display oxidative damage. L-carnitine alone was associated with protein oxidative damage, and al-
tered antioxidant defense. Patients receiving L-carnitine showed similar results to non-supplemented 
patients with regards to oxidative stress. Future mechanistic studies on the role of oxidative stress in 
MCAD deficiency are required.
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